Confirmed
One controlled phase 3 trial met its main goal, and onabotulinumtoxina is approved for this use.
Onabotulinumtoxina: improve symptoms or function in MS (type not specified)
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
MS (type not specified) · Bladder
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 5
- Running now
- 0
- Controlled phase 2/3 trials
- 5
- People in controlled trials
- 733
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 4
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2016 · Placebo-controlled · MSFT-NCT02660359
Phase 3 · 2016 · Placebo-controlled · MSFT-NCT02660138
- Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)decides the statusMet main goal
Phase 3 · 2012 · Placebo-controlled · MSFT-NCT01600716
OnabotulinumtoxinA vs placebo significantly reduced UI at week 6 (-3.3 episodes/day vs -1.1 episodes/day, p < 0.001; primary endpoint).
Read by software from the paper's abstract - Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivitydecides the statusNo result found
Phase 3 · 2006 · Placebo-controlled · MSFT-NCT01091727
Other linked trials: 4
These linked trials do not set the status.
Phase 2 · 2011 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-30Status changed from Results pending to Confirmed
- 2026-10-27First listed as Results pending
Related hypotheses
- Fesoterodine: improve symptoms or function in MS (type not specified)
- Mirabegron: improve symptoms or function in MS (type not specified)
- Onabotulinumtoxina: improve symptoms or function in relapsing and progressive MS
- Tamsulosin: improve symptoms or function in MS (type not specified)
- Onabotulinumtoxina: improve symptoms or function in relapsing and progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error